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Synapsins are neuronal phosphoproteins that coat synaptic vesicles and are believed to function in
the regulation of neurotransmitter release. The signaling mechanism for short-chain free fatty acid
(SCFA)-stimulated NE release was examined using primary-cultured mouse sympathetic cervical
ganglion neurons. Pharmacological and knockdown experiments showed that activation of sympa-
thetic neurons by SCFA propionate involves SCFA receptor GPR41 linking to Gbc-PLCb3-ERK1/2-syn-
apsin 2 signaling. Further, synapsin 2b directly interacts with activated ERK1/2 and can be
phosphorylated on serine when SCFA activates sympathetic neurons.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Recently, the ligands of several orphan G protein-coupledThe sympathetic nervous system (SNS) plays an essential role in
the maintenance of body homeostasis. The SNS can be regulated by
various stimuli, including free fatty acids (FFAs) [1–4]. An infusion
of the long-chain fatty acid oleate (C18:1) increases blood pressure
in rats, and the effect can be abolished by the a1-adrenoceptor
blocker prazosin, which indicates that long-chain fatty acids en-
hance sympathetic activity [5]. In addition, an infusion of the
short-chain fatty acid (SCFA) acetate (C2) causes an increase in
blood pressure, heart rate, and energy expenditure in normal hu-
mans [6], which suggests that SCFAs activate the SNS. However,
the mechanism by which fatty acids induce sympathetic activation
is unclear.chemical Societies. Published by E
, G protein-coupled receptor;
; FFAs, free fatty acids; SCG,
; Dox, doxycycline; [3H]-NE,
ﬁed Eagle’s medium/nutrient
buffer; PTX, pertussis toxin;
ic Drug Discovery Science,
ciences, Sakyo-ku, Kyoto 606-
ke@f01.mbox.media.kyoto-u.receptors (GPCRs)—GPR40, GPR41, GPR43, GPR84, GPR119, and
GPR120—have been identiﬁed, and were found to be FFAs. The ago-
nists of GPR40, GPR84, GPR119 and GPR120 are long- and med-
ium-chain fatty acids [7–11], and those of GPR41 and GPR43 are
SCFAs [12–15]. We have recently found that GPR41 is expressed
abundantly in sympathetic ganglia and that SCFAs directly activate
the SNS via GPR41 at the level of the ganglion [16]. In addition, we
found that the SCFA propionate (C3) has the most potent agonistic
effect on GPR41, whereas the ketone body b-hydroxybutyrate acts
as an antagonist of GPR41 in heterologous expression systems [16].
However, the detailed signaling pathway for GPR41-mediated
sympathetic activation remains uncertain. In the present study,
we clariﬁed the signaling mechanism for the GPR41-mediated re-
lease of NE using primary-cultured mouse sympathetic cervical
ganglion (SCG) neurons as a model. The ﬁnding provides a new in-
sight into the mechanism of GPR41-mediated sympathetic activa-
tion by SCFAs.
2. Materials and methods
2.1. Animals
All experimental procedures involving mice were carried out
according to protocols approved by the relevant animal ethicslsevier B.V. All rights reserved.
1548 D. Inoue et al. / FEBS Letters 586 (2012) 1547–1554committees. Postnatal day 1 (P1) C57/BL6J mice were purchased
from Shimizu Laboratory Supplies Co., Ltd. Gpr41/ mice were
generated as previously described [16] and backcrossed 11 times
into C57BL/6J background.
2.2. Cell culture
Primary culture of SCG neurons was performed as described
previously [16]. For quantitative RT-PCR analysis, cells were incu-
bated at 37 C for 24 h. For immunoprecipitation, Western blot
analysis, and NE release assay, cells were incubated at 37 C for
96 h before assay. HEK293 cells expressing doxycycline (Dox)-
inducible mouse GPR41 is cultured as described previously [16].
2.3. Plasmid construction and transfection
Mouse synapsin 2b expression plasmid was constructed by
ligating synapsin 2b complementary DNA into the mammalian
expression vector pcDNA3.1 (Invitrogen) with the amino-terminal
HA tag. S426A mutant of synapsin 2b was generated using the
PrimeSTAR Mutagenesis Basal kit (TaKaRa). The primers used were
50-GCCCTGGCTCCACAGAGACCTTTAACC-30 and 50-CTGTGGAGCCAG
GGCAGGAGTCCTGGA-30. HEK293 cells expressing Dox-inducible
mouse GPR41 was transfected using Lipofectamine 2000 (Invitro-
gen). After 24 h, GPR41 protein expression was induced by adding
doxycycline hyclate (10 lg/ml, Sigma), and incubated at 37 C for
48 h before assay.
2.4. RNA isolation and quantitative RT-PCR
Total RNA was extracted from primary-cultured SCG neurons
or P1 SCG using RNeasy Mini Kit (Qiagen). Then cDNA was synthe-
sized and analyzed by quantitative RT-PCR [16–18]. After an initial
incubation for 30 s at 95 C, cDNA was ampliﬁed 40 cycles of PCR
(95 C, 5 s, 60 C, 30 s). Expression was quantiﬁed in triplicate.
The primers used were 50-CCTGAATGGCAGAAAACCTG-30 and 50-
TGAATGGGATGGAGAGGAAG-30 for Synapsin1, 50-GGGTGTTTGCTCA
GATGGTG-30 and 50-TCTCTCGGTGATTGGGGTAG-30 for Synapsin2,
50-GATGAAGCCAAAGCGGAGAC-30 and 50-GCACAAAGGAACAGAGG
AAGG-30 for Synapsin2a, 50-TGCTGACTGGACTGTTTCTCC-30 and
50-AGTGGCTGTTTCTCCCAACC-30 for Synapsin2b, 50-TCGATGACG
CCCATACAGAC-30 and 50-GGTAACATAAGCAGCCAGGTTC-30 for Syn-
apsin3, 50-CTCAACACGGGAAACCTCAC-30 and 50-AGACAAATCGCTCC
ACCAAC-30 for 18S.
2.5. siRNA transfection
Cells were nucleofected as described [19]. siRNAs used were
50-UUGAUAAGCAGAUUGGAAGGCUUCA-30 for Erk1[16], 50-AUAA
UACUGCUCCAGGUAUGGGUGG-30 for Erk2 [16], 50-AUUUGAUGA
ACUUACUCCCGCGCCG-30 for Plcb3 [16], 50-AAAUGUAGUCUUUG
CCAUCUUUGCC-30 for Synapsin2 (#1), 50-UUAAAGGUCUCUGUGG
AGACAGGGC-30 for Synapsin2 (#2), 50-AUGACUAGAUCAGUGAUGA
GUUGUC-30 for Synapsin2 (#3). Stealth RNAi™ siRNA Negative Con-
trol LO GC (Invitrogen) was used as a non-speciﬁc control.
2.6. Tritium-labeled norepinephrine release assay
Tritium-labeled norepinephrine ([3H]-NE) release assay was
performed essentially as described [20]. Cells were labeled with
1.5 lCi/well levo-[ring-2,5,6-3H] norepinephrine (1 mCi/ml; Perk-
inElmer Life Sciences) in Dulbecco’s modiﬁed Eagle’s medium/
nutrient Ham’s mixture F-12 (D/F) medium containing 10% FBS
for 1 h at 37 C. For treatments, cells were washed with PBS and
preincubated for 30 min at 37 C in Krebs Ringer bicarbonate buffer
(KRB; 136 mM NaCl, 4.7 mM KCl, 10 mM NaPO4, 0.9 mM MgSO4,and 0.9 mM CaCl2, pH 7.4) to which desipramine (0.6 lM) and cor-
ticosterone (40 lM) had been added, in the presence or absence of
inhibitors; b-hydroxybutyrate (1 mM; Sigma), NF023 (20 lM; Cal-
biochem), Gallein (10 lM; Calbiochem), Pertussis toxin (PTX; 1 lg/
ml; Wako), U73122 (5 lM; Wako), U73343 (5 lM; Wako), and
U0126 (10 lM; Promega). Desipramine and corticosterone were
added for blockade of the neuronal and extraneuronal uptake of
norepinephrine, respectively [21]. The cells were subsequently
stimulated by the addition of KRB containing desipramine and cor-
ticosterone, with either propionate or Carbachol at indicated con-
centrations, with or without inhibitors for 15 min at 37 C.
2.7. Immunoprecipitation and Western blotting
Cells were starved medium without FBS or NGF for 5.5 h at
37 C and then incubated in medium with or without inhibitors
for 30 min at 37 C. Subsequently, the cells were stimulated with
propionate (10 mM) for 10 min with or without inhibitors and
harvested as described [22]. The cell lysates immunoprecipitated
with anti-synapsin 2 (10 lg/ml; Synaptic Systems), anti-HA
(1:50, Roche), as described [23].
Western blot analysis was performed as described [22]. The
antibodies used ware anti-b-actin (1:1000; Sigma), anti-PLCb3
(1:1000; Cell Signaling Technology), anti-total-ERK1/2 (1:1000;
Cell Signaling Technology), anti-phospho-ERK1/2 (1:1000; Cell
Signaling Technology), anti-Phosphoserine (1:1000; Abcam), anti-
synapsin 2 (1 lg/ml), anti-HA (1:1000), anti-rabbit IgG (1:5000;
GE Healthcare UK) and anti-mouse IgG (1:5000; GE Healthcare UK).
2.8. Statistical analysis
Values are presented as mean ± SEM. Differences between
groups were examined for statistical signiﬁcance using ANOVA fol-
lowed by Tukey–Kramer multiple comparison test. P values of
<0.05 were considered statistically signiﬁcant.
3. Results
3.1. SCFAs increase release of NE from sympathetic neurons via GPR41
First, we investigated the effect of SCFAs on NE release in pri-
mary-cultured mouse SCG neurons. The [3H]-NE release assay
showed that the nicotinic acetylcholine receptor agonist Carbachol
[24] increased NE release (Fig. 1A). Also, propionate stimulated the
release of [3H]-NE from SCG neurons in a dose-dependent manner
(Fig. 1A). However, b-hydroxybutyrate, a ketone body that was
found to have an antagonistic effect on GPR41 [16], did not affect
NE release, although it signiﬁcantly suppressed the propionate-in-
duced release of NE (Fig. 1B). Furthermore, the propionate-induced
release of NE was abolished in SCG neurons obtained from Gpr41/
mice (Fig. 1C), although Carbachol-induced release of NE was com-
parable between wild-type and Gpr41/ SCG neurons (Fig. 1C).
These results showed that propionate increases the release of NE
from primary-cultured mouse SCG neurons via GPR41.
3.2. Propionate-induced release of NE involves Gbc, PLCb3, and ERK1/2
Next, we examined the intracellular signaling pathway for
GPR41-mediated release of NE in primary-cultured mouse SCG
neurons. Pretreatment with pertussis toxin (PTX) signiﬁcantly
suppressed propionate-induced NE release (Fig. 2A), which indi-
cated the involvement of Gi/o (Fig. 2A). Furthermore, the Gbc inhib-
itor Gallein signiﬁcantly suppressed the propionate-induced
release of NE, whereas the Gai/o inhibitor NF023 showed no inhib-
itory effect (Fig. 2A), which indicated the involvement of Gbc but
not Gai/o. The PLC inhibitor U73122 and the MEK inhibitor
Fig. 1. Propionate increases NE release from sympathetic neurons via GPR41. (A)
Propionate (1 or 10 mM)-induced release of [3H]-NE from SCG neurons (n = 4). (B)
Effect of pretreatment with b-hydroxybutyrate (1 mM) on propionate (10 mM)-
induced NE release (n = 4). (C) Release of [3H]-NE from wild-type and Gpr41/ SCG
neurons following stimulation with propionate (10 mM) (n = 3). (A–C) Carbachol
(50 lM) was used as a positive control in each experiment. ⁄P < 0.05; ⁄⁄P < 0.01.
Fig. 2. Propionate-induced release of NE involves Gbc, PLCb3, and ERK1/2. (A)
Effects of inhibitors; NF023 (20 lM), Gallein (10 lM), PTX (1 lg/ml), U73122
(5 lM), U73343 (5 lM), and U0126 (10 lM) on propionate (10 mM)-induced
release of [3H]-NE in SCG neurons (n = 4). (B) Effects of siRNA treatment on protein
expression in SCG neurons. Expression of PLCb3 and ERK1/2 protein was measured
by Western blotting. b-Actin expression was used as an internal control. (C) Effects
of siRNA treatment on propionate (10 mM)-induced release of [3H]-NE in SCG
neurons (n = 4). (A and C) Values are presented as the percentage of propionate-
stimulated NE release relative to the corresponding control. ⁄⁄P < 0.01.
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whereas U73343, an inactive analog of U73122, had no inhibitory
effect. Moreover, treatment with an siRNA against either PLCb3
or ERK1/2, which decreased expression of the target protein bymore than 80% (Fig. 2B), signiﬁcantly inhibited propionate-induced
release of NE (Fig. 2C). These results showed that the propionate-
induced release of NE from sympathetic neurons involves Gbc,
PLCb3, and ERK1/2.
Fig. 3. Propionate-induced ERK1/2 phosphorylation involves Gbc and PLCb3. (A)
Effects of inhibitors; NF023 (20 lM), Gallein (10 lM), PTX (1 lg/ml), U73122
(5 lM), U73343 (5 lM), and U0126 (10 lM) on propionate (10 mM)-induced ERK
phosphorylation in SCG neurons as measured byWestern blotting (n = 4). (B) Effects
of siRNA treatment on propionate (10 mM)-induced ERK phosphorylation in SCG
neurons as measured by Western blotting (n = 4). ⁄P < 0.05; ⁄⁄P < 0.01.
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To examine the relationship among Gbc, PLCb3, and ERK1/2, we
examined whether propionate-induced ERK1/2 phosphorylation in
SCG neurons involves Gbc and PLCb. Pretreatment with PTX, Gal-
lein, U73122, or U0126 signiﬁcantly suppressed propionate-in-
duced ERK1/2 phosphorylation in SCG neurons (Fig. 3A). In
contrast, NF023 and U73343 showed no inhibitory effects on pro-
pionate-induced ERK1/2 phosphorylation (Fig. 3A). In addition,
treatment with an siRNA against PLCb3 signiﬁcantly suppressed
propionate-induced ERK1/2 phosphorylation (Fig. 3B). These re-
sults indicate that propionate-induced ERK1/2 phosphorylation in-
volves Gbc and PLCb3.
3.4. Propionate-induced release of NE involves synapsin 2
The synapsins are a family of synaptic vesicle-associated phos-
phoproteins, and are thought to be involved in the modulation of
neurotransmitter release by controlling the availability of synaptic
vesicles for exocytosis [25,26]. Quantitative RT-PCR showed that
Synapsin2 is the most abundantly expressed among the three iso-
forms (Synapsin1, 2, and 3) in mouse SCG neurons (Fig. 4A). Treat-
ment with siRNAs against synapsin 2 decreased both mRNA and
protein expression of synapsin 2 by more than 70% (Fig. 4B and
C), while they did not affect the protein expression of either
ERK1/2 or PLCb3 (data not shown). siRNA-mediated knockdown
of synapsin 2 had no effect on the basal level of NE release, but sig-
niﬁcantly suppressed propionate-induced release of NE in SCG
neurons (Fig. 4D). The results showed that synapsin 2 is involved
in the propionate-induced release of NE from SCG neurons.
3.5. Activated ERK1/2 phosphorylates serine 426 of synapsin 2b
Propionate induced approximately 2-fold increase in the serine
phosphorylation of synapsin 2 in primary cultured SCG neurons of
wild-type mice, whereas this effect was not observed in SCG
neurons of Gpr41/ mice (Fig. 5A). This ﬁnding showed that the
propionate-stimulated activation of GPR41 results in serine phos-
phorylation of synapsin 2. Next, we examined the relationship
between activation of ERK1/2 and serine phosphorylation of
synapsin 2 in SCG neurons. The propionate-induced serine phos-
phorylation of synapsin 2 was completely inhibited by pretreat-
ment with U0126 or siRNA-mediated knockdown of ERK1/2
(Fig. 5B and C), which indicated the involvement of ERK1/2. Fur-
thermore, we examined whether ERK1/2 can form a complex with
synapsin 2. The immunoprecipitation experiments showed that no
complex was formed between synapsin 2 and ERK1/2 in the
absence of propionate stimulation, whereas a marked association
between synapsin 2 and ERK1/2 was observed upon activation
with propionate (Fig. 5D). The ERK1/2 in the complex included
phosphorylated ERK1/2 (Fig. 5D). Furthermore, the propionate-
stimulated formation of a complex between synapsin 2 and ERK1/
2 was inhibited completely by U0126 pretreatment (Fig. 5D),
which indicated that phosphorylated ERK1/2 is associated predom-
inantly with synapsin 2.
In order to determine the phosphorylation sites of synapsin 2 by
ERK1/2, we performed mass spectrometry (MS) analysis and muta-
tion experiments. Synapsin2 can be alternatively spliced to gener-
ate isoforms 2a and 2b [26], and Synapsin2b is abundantly
expressed compared with Synapsin2a in SCG neurons (Fig. 5E).
The LC–MS/MS analysis identiﬁed the phosphorylation site at
serine 426, which is recognized by proline-directed protein
kinases, including ERK1/2 (Fig. S1A). Propionate enhanced phos-
phorylation of the peptide containing serine 426 (Fig. S1B). In
addition, we examined the effect of propionate treatment on phos-phorylation of either wild-type and S426A mutated synapsin 2b.
Western blot analysis of HEK293 cells expressing GPR41 with
phosphoserine antibody showed that propionate increased the
phosphorylation of wild type synapsin 2b, but it had no effect on
the phosphorylation of S426A synapsin 2b (Fig. 5F). These results
Fig. 4. Propionate-induced release of NE involves synapsin 2. (A) Expression of Synapsin1, Synapsin2, and Synapsin3 mRNA in P1 SCG as measured by quantitative RT-PCR
(n = 3). (B) Knockdown efﬁciencies of Synapsin2 siRNA (#1–#3) in SCG neurons as measured by quantitative RT-PCR. Expression of 18S rRNA was used as an internal control.
(C) Effects of Synapsin2 siRNA (#1–#3) treatment on the expression of synapsin 2 protein in SCG neurons as measured by Western blotting. b-Actin expression was used as an
internal control. (D) Effects of siRNA against synapsin 2 (#1–#3) on propionate (10 mM)-induced release of [3H]-NE in SCG neurons (n = 4). ⁄P < 0.05.
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ERK1/2. Taken together, our results showed that activated ERK1/
2 forms a complex with synapsin 2b, which may then lead to serine
426 phosphorylation of synapsin 2b.4. Discussion
In the present study, we showed that activation of GPR41 by
SCFAs directly facilitates the release of NE from sympatheticneurons via the Gbc-PLCb3-ERK1/2-synapsin 2 pathway. In gen-
eral, activation of Gi/o protein-coupled receptors, such as a2-
adrenoceptors and the adenosine A1 receptor, inhibits the release
of NE from sympathetic neurons, whereas activation of Gs
protein-coupled receptors such as b-adrenoceptors and Gq/11
protein-coupled receptors such as the angiotensin AT1 receptor
facilitate NE release [27]. The underlying mechanism by which
Gi/o protein-coupled receptors mediate the inhibition of NE release
in sympathetic neurons involves an inhibition of adenylyl cyclase
by Gai/o and a blockade of voltage-gated Ca2+ channels by Gbc
Fig. 5. Activated ERK1/2 causes serine phosphorylation of synapsin 2b. (A) Effects of propionate (10 mM) on Synapsin 2 serine-phosphorylation in wild-type and Gpr41/
SCG neurons as measured by Western blotting (n = 4). IP; immunoprecipitation. (B) Effects of pretreatment with U0126 (10 lM) for 30 min on propionate (10 mM)-induced
Synapsin 2 phosphorylation in SCG neurons as measured by Western blotting (n = 4). (C) Effects of ERK1/2 knockdown on propionate (10 mM)-induced Synapsin 2
phosphorylation in SCG neurons as measured by Western blotting (n = 4). (D). Effects of U0126 (10 lM) on propionate (10 mM)-induced interaction between Synapsin 2 and
ERK1/2 as measured by Western blotting (n = 3). (E) Expression of Synapsin2a, Synapsin2b mRNA in P1 SCG as measured by quantitative RT-PCR (n = 3). (F) Effects of
propionate (10 mM) on wild or S426A-mutated HA-synapsin 2b serine-phosphorylation in GPR41-expressing HEK293 cells measured by Western blotting (n = 3). IP;
immunoprecipitation. (A–D, F) Representative exposures of three to four experiments are shown. As a control, the relative quantities of synapsin 2 (A–C) and synapsin 2b (F)
in the immunoprecipitates, and ERK1/2 in the cell lysates (D) are shown. ⁄⁄P < 0.01.
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protein-coupled receptor GPR41. Furthermore, the results of our
study showed that Gbc that is released from Gi/o following SCFA
stimulation of GPR41 directly activates the PLCb3-ERK1/2-synap-
sin 2 pathway, and thereby facilitates the release of NE. Although
this Gi/o protein-coupled receptor GPR41-mediated release of NE
appears to be uncommon, similar stimulatory response of sympa-
thetic neurons was indicated for other Gi/o protein-coupled recep-
tors [28]. Thus, activation of the a2-adrenoceptor enhances
angiotensin II-induced NE release, and this response is attenuated
by a Gbc inhibitor, which suggests that AT1 receptor-mediated
activation of PLC can be further enhanced by released Gbc follow-
ing stimulation of the a2-adrenoceptor [28]. Our study clearly
demonstrated that activation of a Gi/o protein-coupled receptor
can directly facilitate NE release via Gbc, but the functional role
of Gai/o that is activated following the stimulation of GPR41 re-
mains to be elucidated.
The results of our study further showed that the SCFA-induced
release of NE from sympathetic neurons is mediated, at least in
part, by the ERK1/2-synapsin 2 pathway. Phosphorylation of syn-
apsin 2 in adrenal medullary chromafﬁn cells was reported previ-
ously [29], but the biological signiﬁcance and biochemical
mechanism of synapsin 2 phosphorylation in sympathetic neurons
remained unclear. The present study showed that phosphorylation
of synapsin 2 is a component of the SCFA-induced release of NE in
sympathetic neurons, and further demonstrated that activated
ERK1/2 stimulates serine phosphorylation of synapsin 2. Whereas
ERK1/2 in neurons has been shown to play an important role in
the regulation of gene expression [30], recent experimental evi-
dence suggests that ERK1/2 exerts additional actions by directly
phosphorylating synaptic protein substrates such as synapsins
[30,31]. Synapsins are suggested to regulate the availability of syn-
aptic vesicles for release in a phosphorylation-dependent manner
[26]. In fact, brain-derived neurotrophic factor-induced release of
the neurotransmitter glutamate was shown to involve ERK1/2-
dependent phosphorylation of synapsin 1 in a synaptosomal prep-
aration of the rat cerebral cortex [31]. Our study showed for the
ﬁrst time that ERK1/2-mediated serine phosphorylation of synap-
sin 2 plays an important role in ligand-stimulated sympathetic
neurons. Given that the extent of the reduction in SCFA-induced
NE release was closely correlated with the efﬁciency of the siR-
NA-mediated knockdown of synapsin 2 (Fig. 4), ERK1/2-synapsin
2 signaling appears to be a major signaling pathway for the
GPR41-mediated activation of sympathetic neurons.
As described in Section 1, a recent GPCR de-orphanizing strat-
egy has successfully identiﬁed a family of receptors that are acti-
vated by FFAs. Utilizing mice that lack a member of this GPCR
family, we have recently observed that SCFAs directly activate
the SNS via GPR41 at the level of the ganglion, and showed that
SCFAs contribute to the regulation of energy homeostasis via
GPR41 [16]. Using primary cultured sympathetic neurons, the
present study further demonstrated that the SCFA receptor
GPR41 is coupled with Gi/o protein, but stimulates the release of
NE via Gbc-PLCb3-ERK1/2-synapsin 2 pathway. These studies
clearly show the biological signiﬁcance and signaling mechanism
of the SCFA receptor GPR41, and further support the idea that FFAs
can act as signaling molecules in various physiological processes.
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